|
Market Closed -
Nasdaq
21:00:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8600 USD | -4.09% |
|
-13.39% | -83.99% |
| 09-23 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 09-23 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 155M | - | - | - | - | - |
| 65B | |||||
| 51.19B | |||||
| 51.2B | |||||
| 43.93B | |||||
| 41.96B |
Select your edition
All financial news and data tailored to specific country editions
